Metraipolis › archive › dc_45efac45b379

Current Status of Molecularly Targeted Therapeutics in Blood Cancers — Europe PMC PMID:41226551

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41226551
DOI
10.3390/ijms262110512
License (as archived)
solo-consultazione
Archived
2026-11-08T23:38:02.129Z
SHA-256 of the archived text
13570c08f6e0f9f376c3827ad8c50dbfbf59800505ffaa9e37a59951d7dcf314
Stable URL of this page
https://metraipolis.com/documento/dc_45efac45b379

How to cite

Current Status of Molecularly Targeted Therapeutics in Blood Cancers — Europe PMC PMID:41226551 — Europe PMC (en), https://europepmc.org/article/MED/41226551 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_45efac45b379 (Metraipolis archive dc_45efac45b379, sha256 13570c08f6e0f9f376c3827ad8c50dbfbf59800505ffaa9e37a59951d7dcf314)
BibTeX
@misc{dc45efac45b379,
  title = {Current Status of Molecularly Targeted Therapeutics in Blood Cancers — Europe PMC PMID:41226551},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41226551},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_45efac45b379; sha256 13570c08f6e0f9f376c3827ad8c50dbfbf59800505ffaa9e37a59951d7dcf314},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41226551. Agents can read the archived copy with the MCP tool read_document.